Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Thai opposition figure says government seeks to silence him on vaccine

Published 21/01/2021, 14:30
Updated 21/01/2021, 14:35
© Reuters. Thai banned opposition politician holds news conference on royal company's role in vaccine strategy

By Patpicha Tanakasempipat

BANGKOK (Reuters) - A banned Thai opposition politician, who is facing a criminal complaint of defaming the monarchy, on Thursday defended his criticism of the government's coronavirus vaccine strategy that relies on a company owned by King Maha Vajiralongkorn.

Thanathorn Juangroongruangkit this week accused the government of mishandling the vaccine campaign, saying it was too reliant on Siam Bioscience and will be slow to protect the public because of its failure to negotiate multiple deals.

The Thai company is owned by the Crown Property Bureau, which manages tens of billions of dollars in investment under the king's personal control.

Siam Bioscience, which received a 600 million baht ($20 million) government subsidy to develop its production capacity, agreed in October to manufacture AstraZeneca Plc's COVID-19 vaccine and supply it domestically and across Southeast Asia.

Thailand has so far recorded just 12,795 infections and 71 deaths from COVID-19. Its Food and Drug Administration has approved the AstraZeneca vaccine for emergency use, three senior health ministry sources told Reuters on Thursday.

Thanathorn had alleged the AstraZeneca deal lacked transparency and Siam Bioscience was given an unfair advantage over other companies.

On Wednesday, the government lodged a criminal complaint against Thanathorn for his criticism, accusing him of royal insult that is punishable by up to 15 years in prison.

Thanathorn denied making allegations of the king's involvement in the vaccine deal and said the government's complaint was politically motivated to silence him.

"I questioned whether the scheme benefited one single company or not. It just happened that the shareholder of the company is the king himself," he told Reuters in an interview.

A government spokeswoman, Ratchada Dhanadirek, has denied the prosecution was politically motivated.

Siam Bioscience declined to comment on Thanathorn's allegations.

An AstraZeneca spokesman said the firm had an established network of partners to deliver doses as quickly as possible.

"All manufacturing partners are subject to compliance with the international Current Good Manufacturing Practices," the spokesman said, referring to regulatory standards.

Thanathorn was banned from politics for 10 years after a court dissolved his Future Forward Party last year over loans deemed illegal.

The party won support among younger voters in a 2019 election, coming third, with a campaign that focused on opposition to military influence over politics.

The government said the election was free and fair but opposition parties say it was designed to ensure former junta leader Prayuth remained in power.

© Reuters. Thai banned opposition politician holds news conference on royal company's role in vaccine strategy

($1 = 29.9400 baht)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.